A
1.52
0.07 (4.83%)
| Penutupan Terdahulu | 1.45 |
| Buka | 1.44 |
| Jumlah Dagangan | 1,576,232 |
| Purata Dagangan (3B) | 2,760,648 |
| Modal Pasaran | 165,910,240 |
| Harga / Jualan (P/S) | 2.81 |
| Harga / Buku (P/B) | 3.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -139.74% |
| Margin Operasi (TTM) | -1,216.52% |
| EPS Cair (TTM) | -1.26 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -76.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.39% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | -229.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -92.86 M |
| Pulangan Atas Aset (ROA TTM) | -17.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -90.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Alector, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.61% |
| % Dimiliki oleh Institusi | 80.74% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Dec 2025 | Pengumuman | Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer |
| 01 Dec 2025 | Pengumuman | Alector to Participate in the Bank of America CNS Therapeutics Conference |
| 06 Nov 2025 | Pengumuman | Alector Reports Third Quarter 2025 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |